about
Immunocytochemical demonstration of the equilibrative nucleoside transporter rENT1 in rat sinoatrial nodeAdenosine kinase regulation of cardiomyocyte hypertrophy.Cardiac purinergic signalling in health and diseaseInhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection.Understanding myocardial ischemic preconditioning, and the implications for a role of adenosine catabolism.The diabetic heart: too sweet for its own good?Dipyridamole enhances ischaemia-induced reactive hyperaemia by increased adenosine receptor stimulation.Transport characteristics of HL-1 cells: a new model for the study of adenosine physiology in cardiomyocytes.Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line.The protective effects of preconditioning on cerebral endothelial cells in vitro.Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole.Exercise improves hemodynamic profiles and increases red blood cell concentrations of purine nucleotides in a rodent model.Role of nitric oxide/cyclic GMP in myocardial adenosine A1 receptor-inotropic response.Highly selective A(1) -adenosine-agonist (2-chloro-N6-cyclopentyladenosine) and reduction of flap necrosis in adipocutaneous flaps in rats.Pyruvate-dependent preconditioning and cardioprotection in murine myocardium.Myocardial adenosine does not correlate with the protection mediated by ischaemic or pharmacological preconditioning in rat heart.Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat.Initiation of remote microvascular preconditioning requires K(ATP) channel activity.Ozone oxidative preconditioning is mediated by A1 adenosine receptors in a rat model of liver ischemia/ reperfusion.Mechanisms involved in adenosine pharmacological preconditioning-induced cardioprotection.The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation.Adenosine 5'-Triphosphate Metabolism in Red Blood Cells as a Potential Biomarker for Post-Exercise Hypotension and a Drug Target for Cardiovascular Protection.
P2860
Q28567094-7497FE57-436F-470D-BFD8-65DADAA66A26Q29347052-9D869A65-F435-42AE-ABFE-AAF90C587CF4Q33165093-6FCBF401-EC06-4C94-9ECA-1819DD754F5EQ34049167-EA48944F-3DBF-422F-91F5-9C5E894FA67CQ35072009-F11D74A5-FF1D-423D-B04D-669A6AFC902EQ35810679-5B9513DB-46F6-4341-ABED-01C71A5BE2E3Q36510022-3828FB77-8736-4326-9035-F8E2B440D6F7Q38360778-D22D8EE7-202A-4E2A-9500-8F23C6633E57Q39990412-D7FCAD48-B353-4129-8916-E36DCF8C6FD5Q40619450-685ADB0E-BF98-4961-9708-FC3A77FAB497Q40627376-54140054-C892-4A27-A7ED-CA9898BC937AQ42851008-E5A172B0-BE4B-47CF-BA58-3FF4D40A772FQ43263979-E0DD5A29-711E-49A2-85B1-B5D14EF4043FQ43755499-06E7EA0E-534E-4497-943D-192060C8C86BQ44326254-0D710498-3244-4B07-A320-B24AB3F10406Q44512020-AC7574B5-B25A-4DA1-9277-3C8D6A57D2BBQ45022809-3095C2FC-13FB-4379-9BBB-70DB55559F8AQ46673652-31471F2B-1869-4EC5-BF5D-E38AC3017B7FQ46957551-46163E2F-2B5E-448F-BA7E-9AAF401BA1E9Q54112980-845B49FC-1B13-4896-8395-F914FF822A29Q54497300-D80818C5-3359-405D-86E2-B47B7A48E105Q55618500-B1C936CA-81B4-40C6-AB92-4360AAE3FADC
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The role of adenosine in preconditioning.
@ast
The role of adenosine in preconditioning.
@en
The role of adenosine in preconditioning.
@nl
type
label
The role of adenosine in preconditioning.
@ast
The role of adenosine in preconditioning.
@en
The role of adenosine in preconditioning.
@nl
prefLabel
The role of adenosine in preconditioning.
@ast
The role of adenosine in preconditioning.
@en
The role of adenosine in preconditioning.
@nl
P2093
P1476
The role of adenosine in preconditioning.
@en
P2093
Bradamante S
de Jong JW
de Jonge R
P304
P356
10.1016/S0163-7258(00)00044-9
P577
2000-08-01T00:00:00Z